DrugPatentWatch Database Preview
VERZENIO Drug Profile
When do Verzenio patents expire, and what generic alternatives are available?
Verzenio is a drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this drug.
This drug has forty-five patent family members in forty-one countries.
The generic ingredient in VERZENIO is abemaciclib. One supplier is listed for this compound. Additional details are available on the abemaciclib profile page.
Summary for VERZENIO
| International Patents: | 45 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 53 |
| Clinical Trials: | 11 |
| Drug Prices: | Drug price information for VERZENIO |
| DailyMed Link: | VERZENIO at DailyMed |
Generic Entry Opportunity Date for VERZENIO
Generic Entry Date for VERZENIO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VERZENIO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| University of Texas Southwestern Medical Center | Phase 2 |
| National Cancer Institute (NCI) | Early Phase 1 |
Pharmacology for VERZENIO
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Kinase Inhibitors |
Synonyms for VERZENIO
| [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine |
| 1231929-97-7 |
| 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) |
| 2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]- |
| 3798AH |
| 60UAB198HK |
| 6ZV |
| Abemaciclib |
| Abemaciclib (JAN/USAN) |
| Abemaciclib (ly2835219) |
| Abemaciclib [USAN:INN] |
| Abemaciclib,LY2835219 |
| AK174895 |
| AKOS025404907 |
| AS-10230 |
| AX8323622 |
| BCP13079 |
| BDBM50110183 |
| bemaciclib |
| C27H32F2N8 |
| CHEMBL3301610 |
| CS-1230 |
| D10688 |
| DB12001 |
| DTXSID20673119 |
| EX-A1588 |
| EX-A521 |
| FT-0700134 |
| GTPL7382 |
| HY-16297A |
| J-690083 |
| KB-69638 |
| KS-00000T51 |
| LY 2835219 |
| LY 2835219 (free base) |
| LY-2835219 |
| LY-2835219|||N-[5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
| LY2835219 |
| LY2835219 (free base) |
| LY2835219 free base |
| LY2835219 free base (Abemaciclib) |
| LY2835219 Ms salt, Abemaciclib Ms salt |
| MolPort-039-137-732 |
| N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine |
| N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
| N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine |
| N-{5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine |
| NCGC00351599-06 |
| QC-11713 |
| SB16476 |
| SC-82423 |
| SCHEMBL2487229 |
| Tube014 |
| UNII-60UAB198HK |
| UZWDCWONPYILKI-UHFFFAOYSA-N |
| Verzenio (TN) |
| Verzenios |
| W-5974 |
| ZINC72318121 |
US Patents and Regulatory Information for VERZENIO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-004 | Sep 28, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VERZENIO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2379528 | Start Trial |
| Hong Kong | 1159630 | Start Trial |
| Ecuador | SP11011157 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VERZENIO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | PA2019004 | Lithuania | Start Trial | PRODUCT NAME: ABEMACIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| 2379528 | CA 2019 00008 | Denmark | Start Trial | PRODUCT NAME: ABEMACICLIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1307 20181001 |
| 2379528 | LUC00106 | Luxembourg | Start Trial | PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
